BLTE
vs
DPH
BLTE
DPH
Over the past 12 months, BLTE has significantly outperformed DPH, delivering a return of +169% compared to the DPH's 0% growth.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
BLTE
DPH
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Belite Bio Inc
NASDAQ:BLTE
|
159.85
USD
|
|||||
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
3 866
GBX
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
BLTE, DPH
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
Belite Bio Inc
Revenue
|
|||||||||||
|
Dechra Pharmaceuticals PLC
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
BLTE, DPH
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
Belite Bio Inc
NASDAQ:BLTE
|
|||||||||
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|||||||||
Compare company's free cash flow with its competitors.
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Belite Bio Inc | ||||
|
Dechra Pharmaceuticals PLC | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
BLTE, DPH
Performance Gap
BLTE, DPH
Performance By Year
BLTE, DPH
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.